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Objectives: To review the clinical findings and outcome in dogs diagnosed with insulinoma, and to 
 assess which factors are predictors of overall survival. Additionally, to describe the neurological 
 manifestations of this population and their correlation with survival.
Materials and MethOds: Retrospective multicentric study of canine insulinoma cases (2009 to 2020). 
Signalment, clinical history, neurological examination, diagnostic findings, treatment and outcome 
were obtained from clinical records. Univariate and multivariate analyses were used to compare the 
overall survival.
results: One hundred and sixteen cases were included. Median duration of clinical signs before 
 presentation was 1.5 months. The most common presenting clinical signs were weakness (59.5%), 
epileptic seizures (33.6%) and changes in consciousness or behaviour (27.6%). Three dogs were 
suspected to have paroxysmal dyskinesia. Thirty-two dogs had an abnormal neurological examination, 
most commonly showing obtundation (28.1%), decreased withdrawal reflexes (21.9%) and absent 
menace response (18.8%). Overall survival for dogs undergoing surgery (20 months) was significantly 
longer than in medically treated (8 months; adjusted hazard ratio: 0.33; 95% confidence interval: 0.18, 
0.59). Presence of metastases was the only other variable associated with prognosis (adjusted hazard 
ratio 1.72; 95% confidence interval: 1.02, 2.91).
clinical significance: Clinical signs of canine insulinoma are vague and non-specific. Weakness, 
 epileptic seizures and changes in mentation or behaviour were the most commonly reported. Obtunded 
 mentation and forebrain neurolocalisation were the main neurological manifestations. Dogs  undergoing 
surgery had a longer overall survival compared to medically treated cases, and dogs with  metastasis 
had a shorter overall survival regardless of treatment modality. Abnormalities in the neurological 
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INTRODUCTION
Insulinoma is a rare tumour of the pancreatic beta cells that 
secretes insulin and has been most commonly reported in medium 
to large breed dogs (Nelson 2015). Excess insulin secretion causes 
hypoglycaemia and a wide range of clinical signs related to neu-
roglycopenia and to hypoglycaemia-induced catecholamine 
secretion (Goutal et al. 2012). The typical signs reported of this 
condition are mostly derived from old publications and include 
generalised epileptic seizures (48%), collapse (40%), generalised 
weakness (37%), muscle twitching or trembling (20%), ataxia 
(20%), exercise intolerance (15%), pelvic limb weakness (14%) 
and disorientation (10%); with the majority of animals present-
ing with multiple clinical manifestations (Kruth et al.  1982, 
Leifer et al. 1986, Dunn et al. 1993, Tobin et al. 1999, Trifoni-
dou et al. 1998, Moore et al. 2002, Ettinger et al. 2017). Hence, 
severe neurological signs are currently considered as the most 
common complaint. There is a wide range in the duration of 
clinical signs before presentation, with one review by Trifonidou 
et al. (1998) reporting a mean of 21 weeks (range 1 to 183 weeks). 
However, two recent studies reported a median duration of clini-
cal signs of 3 weeks (range 0 to 52 weeks) and 4.1 weeks (0 to 
40 weeks), respectively, suggesting that nowadays dogs are diag-
nosed earlier (Cleland et al. 2020, Del Busto et al. 2020).
Diagnosis of this condition can be challenging due to inter-
mittent and non-specific clinical signs, laboratory abnormalities 
or imaging findings. A presumptive diagnosis can be obtained 
by documenting hypoglycaemia and serum insulin concentra-
tions within or above reference intervals (Ettinger et al. 2017). 
Ultrasound (US) is reported to have a variable low sensitivity for 
detecting the tumour (28 to 75%), with contrast enhanced CT 
having a higher sensitivity of up to 94% (Robben et al.  2005, 
Buishand et al. 2018). Final diagnosis is confirmed by histology 
(Goutal et al. 2012). Treatment regimens include both medical 
and surgical options. Reported overall survival time is variable 
ranging from 2.4 to 6.5 months for medical management and 
12.4 to 65.4 months for surgical management (Tobin et al. 1999, 
Polton et al. 2007,Cleland et al. 2020, Del Busto et al. 2020).
Although there are several publications describing this con-
dition over the years, the clinical presentation is based on old 
literature (Goutal et al.  2012) and recent publications mainly 
focus on diagnostic techniques (Buishand et al. 2018) and surgi-
cal outcome (Cleland et al.  2020, Del Busto et al.  2020). The 
purposes of this study were to retrospectively review the clinical 
findings and outcome in a large group of dogs diagnosed with 
insulinoma and to assess which factors are predictors of overall 
survival, including treatment modality. Additionally, we aimed to 
describe the neurological manifestations of this population and 
their correlation with survival.
MATERIALS AND METHODS
Study design
This was a retrospective multicentric study performed at six 
referral centres. All patients included were client-owned dogs and 
all the investigations performed were obtained during clinically 
indicated procedures. Medical records of dogs with a presump-
tive or final diagnosis of insulinoma presenting from 2009 to 
2020 were examined.
Medical records review
Information obtained from the medical records included signal-
ment, type and duration of clinical signs, physical and neuro-
logical examination, complete blood count, serum biochemistry, 
insulin and fructosamine levels, diagnostic imaging techniques 
(US or CT), histopathology, treatment and, where available, 
follow-up information. Inclusion criteria were: (1) paired glucose 
and insulin measurements, (2) a full neurological examination 
recorded at presentation and neurolocalisation and (3) imaging 
suggestive of an insulinoma with low glucose and normal or high 
serum insulin documented, or histopathological confirmation of 
an insulinoma. Patients were excluded if they had any other con-
current systemic disease.
Clinical findings
Presenting clinical signs as reported by owners were categorised 
based on a modified criteria used by Ettinger et al.  (2017) and 
Goutal et al.  (2012). The categories were: epileptic seizures 
(split into focal or generalised as described by the Epilepsy Task 
Force consensus report) (Berendt et al. 2015); collapse/syncope; 
weakness (split into generalised, pelvic limb and exercise intoler-
ance); ataxia (split into proprioceptive, vestibular or cerebellar); 
changes in consciousness and behaviour (defined as disorienta-
tion, lethargy, anxiousness, pacing or hiding); polyphagia; poly-
uria/polydipsia; blindness; anorexia; vomiting; diarrhoea; muscle 
fasciculations (Lowrie & Garosi  2016); suspected paroxysmal 
dyskinesia (Lowrie & Garosi 2017) and weight loss.
Neurological examination findings and neurolocalisation were 
reviewed. All neurological examinations were performed by a 
board-certified neurologist, internal medicine specialist or by a 
resident of these two specialities under direct supervision. All dogs 
with epileptic seizures were localised to the forebrain. After the 
diagnosis was reached, all cases were classified according to World 
Health Organisation (WHO) stages. Stage I being local disease 
confined to the pancreas, stage II presence of locoregional metas-
tasis or stage III distant metastasis (Owen et al. 1980). Treatment 
modalities were divided in medical management and surgery.
Statistical analysis
Numerical variables were presented as median, interquartile range 
(IQR) and range, and compared between groups with Mann-
Whitney U test. Categorical variables were expressed as counts 
and percentages, and compared between groups using Pearson’s 
chi-squared or Fisher exact test. Dogs that were euthanised 
within 24 hours of establishing the diagnosis of insulinoma were 
not included in the survival analysis (n=9). An odds ratio (OR) 
with 95% confidence interval (CI 95%) was calculated for the 
association between euthanasia during the first 24 hours of pre-
sentation and abnormal neurological examination findings (con-
sidered as a yes or no answer). Survival analysis was performed 
on all dogs allocated in any of the two treatment groups (surgical 
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versus  medical) for which follow-up information was available 
(n=93). Data on overall survival were considered censored if dogs 
stayed alive on the last follow-up appointment (n=32). Death of 
any reason (including euthanasia at presentation, sudden death, 
euthanasia due to recurrence of the disease, financial reasons and 
death due to any other cause) was considered an event. Prognos-
tic factors of the overall survival were first identified using the 
univariable Cox proportional hazard model (dichotomous and 
continuous variables) or the generalised Mantel-Cox log rank 
test (ordinal categorical variables with more than two categories). 
Variables for which the P-value of the between-group compari-
sons or of the univariable survival analysis was below 0.1 were 
entered into the multivariable Cox proportional hazard model as 
potential confounders. The multivariable model aimed to assess 
the role of the type of treatment as an independent prognostic 
factor of overall survival in insulinoma. The model was devel-
oped according to the backward elimination procedure and was 
shown to adhere to proportional hazards assumption based on a 
plot of the scaled Schoenfeld residuals and their lowess smooth 
versus time, natural logarithm of time, Kaplan–Meier estimate, 
rank of time as well as based on the insignificant results of the 
score tests. Crude hazard ratios (HR) and adjusted hazard ratios 
(HRadjusted) with CI 95% were presented to describe the results 
of the univariable and multivariable analysis, respectively. Sur-
vival rates for the entire range of times were estimated using the 
Kaplan–Meier product-limit estimator with CI 95% calculated 
with log-minus-log method. A significance level (α) of 0.05 was 
assumed in all statistical tests except for the univariable survival 
analysis when α was 0.1. The statistical analysis was performed in 
TIBCO Statistica 13.3.0 (TIBCO Software Inc., Palo Alto, CA) 
and IBM SPSS Statistics 24 (IBM Corporation, Armonk, NY).
RESULTS
Signalment
One hundred and twenty-four dogs with insulinoma were identi-
fied. Seven dogs were excluded due to incomplete records (absent 
imaging, neurological examination, or insulin levels) and one dog 
was excluded due to concurrent systemic disease (immune-medi-
ated haemolytic anaemia). A total of 116 dogs met the inclusion 
criteria and were included in the study. Most common represented 
breeds included Crossbreed (32), West Highland White Terrier 
(12), Boxer (12), Springer spaniel (9) and German shepherd dog 
(5). See Data S1 for full list of breeds. Age at presentation ranged 
from 4 to 18 years with the median (IQR) of 9 (8 to 11) years, 
and bodyweight ranged from 2.3 to 44.6  kg with the median 
(IQR) of 21 (12 to 30) kg. Forty-eight (41.4%) dogs were male 
(24; 50% neutered and 24; 50% entire) and 68 (58.6%) dogs 
were female (51; 75% neutered and 17; 25% entire). Duration of 
clinical signs before presentation ranged from 1 day to 24 months 
with the median (IQR) of 1.5 (1 to 3) months.
Clinical signs
Forty-five (38.8%) dogs presented with a single clinical sign, and 
71 (61.2%) dogs presented with a combination of clinical signs. 
Overall, the most common clinical presentation was weakness 
(69/116, 59.5%), which was further split into generalised weak-
ness (54/116, 46.6%), pelvic limb weakness (15/116, 12.9%) 
and exercise intolerance (7/116, 6%), which accompanied gen-
eralised or pelvic limb weakness in seven dogs. For dogs present-
ing with a combination of clinical signs, it was most common 
to present with two signs (34 cases, 29.3%), with weakness and 
episodes of collapse being the most common combination (9/34 
cases). See Table 1 for a summary of all presenting clinical signs. 
Three dogs were suspected to have paroxysmal dyskinesia on 
presentation, based on the owner’s descriptions and the videos 
provided examined by board certified neurologists. See Table 2 
for a detailed description of these cases.
Only eight (6.9%) dogs had abnormal physical examination 
findings, which included a systolic heart murmur (6/8), bilateral 
pelvic limb muscle atrophy (1/8) and a right shoulder subcu-
taneous mass (1/8). Thirty-two (27.6%) dogs had an abnormal 
neurological examination at presentation. The most common 
findings observed were: obtundation (9/32, 28.1%), decreased 
withdrawal reflexes (7/32, 21.9%) and absent menace response 
(6/32, 18.8%; four bilaterally and two unilaterally). See Table 3 
for a full summary of the neurological examination findings. In 
42 (36.2%) of the 116 dogs, neurological signs were localised in 
the forebrain (diffuse brain in 36 and left forebrain in six, based 
on the neurological examination and/or history of generalised 
epileptic seizures). In seven (6%) of 116, neurological signs were 
localised in the peripheral nervous system, in four (3.5%) of 116, 
they were classified as multifocal (all localising in forebrain due 
to epileptic seizures, and in T3-L3 spinal cord segments) and 
one of 116 in each of the following locations: brainstem, T3-L3 
spinal cord segments and L4-S3 spinal cord segments.
Diagnostic findings
Complete blood count and serum biochemistry results were avail-
able for 98 (84.5%) of 116 cases and were largely unremarkable. 
See Data S2. Glucose at presentation varied between 1.1 and 
Table 1. Most common clinical signs reported in 116 dogs 
diagnosed with insulinoma
Clinical sign Number of dogs (percentage)
Weakness 69 (59.5)
• Generalised • 54 (46.6)
• Pelvic limb • 15 (12.9)
• Exercise intolerance • 7 (6)
Epileptic seizures 39 (33.6)
• Generalised seizures • 36 (31)
• Focal seizures • 3 (2.6)




Muscle fasciculations 24 (20.7)
Proprioceptive ataxia 21 (18.1)
Polyphagia 4 (3.4)
Polyuria polydipsia 4 (3.4)
Vomiting 4 (3.4)
Diarrhoea 4 (3.4)
Suspected paroxysmal dyskinesia 3 (2.6)
Anorexia 1 (0.9)
Blindness 1 (0.9)
Weight loss 1 (0.9)
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Table 3. Neurological examination abnormalities detected 
in 32 dogs diagnosed with insulinoma
Neurological 
Examination
Finding – number (% of 32 cases)
Mentation Obtunded – 9 (28.1)
Behaviour Abnormal behaviour (disorientation, lethargy, 
anxiousness) – 6 (18.8)
Posture Generalised tremors – 2 (6.3)
Gait Proprioceptive ataxia of all four limbs – 3 (9.4)
Non ambulatory tetraparesis – 2 (6.3)
Circling to one side – 1 (3.1)
Compulsive pacing – 1 (3.1)
Pelvic limb proprioceptive ataxia – 1 (3.1)
Cranial nerves Decreased/absent menace response – 6 (18.8)
• Bilateral – 4
• Unilateral – 2




Reduced withdrawal reflexes – 7 (21.9)
• All limbs – 5
• Pelvic limbs – 2
Reduced patellar reflex bilaterally – 1 (3.1)
Flaccid limb tone – 2 (6.4)
Proprioception Delayed proprioception in all limbs – 4 (12.5)
Delayed proprioception on one side – 2 (6.3)
Delayed proprioception in both pelvic limbs – 1 (3.1)
Delayed proprioception on one limb – 1 (3.1)






































































































































































































































































































































































































































































































































































6.5 mmol/L with the median (IQR) of 2.0 (1.7 to 2.3) mmol/L. 
Using a value of 3.5 mmol/L or less to define hypoglycaemia, 94% 
(109/116) of cases were hypoglycaemic at initial presentation with 
the median (IQR) of 1.9 (1.7 to 2.2) mmol/L. The remaining 
6% (7/116) had normal glucose levels with the median (IQR) of 
4.3 (3.9 to 4.9) mmol/L, two of which presented with suspected 
paroxysmal dyskinesia. Paired insulin concentration ranged from 
3 to 290 μIU/mL with the median (IQR) of 36 (25 to 50) μIU/
mL. Fructosamine was measured in 32 of 116 cases (27.6%), with 
a median value of 238.5 μmol/L (77 to 324 μmol/L). All animals 
had imaging performed. Fifty-nine (51%) had US, 43 (37%) had 
CT and 14 (12%) had both US and CT. In two cases that had 
only CT, and one case that had only US, a pancreatic lesion was 
not identified but was found at subsequent exploratory laparot-
omy and confirmed on histopathology. Of the 14 animals having 
both US and CT, four tumours were not seen on US but seen on 
CT, and one tumour was not identified on CT but found on US. 
Sixty (51.7%) cases had evidence of metastasis at the time of diag-
nosis. Fifty-two (86.7%) were identified at imaging (US or CT), 
and eight (13.3%) during the surgical procedure without being 
identified on imaging before. Fifty-six (48.3%) cases were classi-
fied as WHO stage I (pancreatic lesion only), 41 (35.3%) stage 
II (local lymph nodes) and 19 (16.4%) stage III (distant spread).
Seven animals with a history of epileptic seizures and two with 
suspected paroxysmal dyskinesia underwent magnetic resonance 
imaging of the brain, three of which had a cerebrospinal fluid 
sample taken at the same point, all of which showed no significant 
findings. One dog, presenting with non-ambulatory tetraparesis, 
reduced withdrawal and reduced tone in all limbs, underwent an 
electromyography, which showed fibrillation potentials and posi-
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Table 4. Demographic and medical characteristics of the study population (93 dogs) included in the survival analysis with 
regards to type of treatment presented and count and percentage unless otherwise stated
Variable Type of treatment P-value
Surgery (n=65) Medical (n=28)
Sex 0.425
Male 29 (44.6) 10 (35.7)
Female 36 (55.4) 18 (64.3)
Castration 48 (73.9) 16 (57.1) 0.111
Age (years) (median, IQR and range) 9, 8 to 11 (4 to 13) 9, 7 to 10 (4 to 18) 0.476
Bodyweight (kg) (median IQR and range) 21.3, 12.1 to 29.8 (2.3 to 42.7) 18.3, 11.4 to 30.3 (2.5 to 42.3) 0.544
Time from clinical signs to diagnosis (months) (median 
IQR and range)†
1.5, 1 to 3 (0.03 to 12) 1.5, 1 to 4 (0.1 to 12) 0.618
Weakness at presentation 39 (60.0) 15 (53.6) 0.564
Seizures at presentation 18 (27.7) 13 (46.4) 0.079
Change in consciousness at presentation 18 (27.7) 11 (39.3) 0.268
Collapse/syncope at presentation 13 (20.0) 5 (17.9) 0.810
Abnormality in neurological examination 16 (24.6) 7 (25.0) 0.969
Glucose at presentation (mmol/L) (median IQR and range) 2.2, 1.9 to 2.5 (1.2 to 6.5) 1.8, 1.4 to 2.2 (1.1 to 4.3) 0.005
WHO staging 0.173
I 25 (38.5) 16 (57.1)
II 29 (44.6) 7 (25.0)
III 11 (16.9) 5 (17.9)
†Data missing for seven dogs replaced by the median of the remaining 91 cases equal to 1.5
A diagnosis of insulinoma was confirmed based on histo-
pathology in 70 cases (60.3%), fine needle aspirate in 6 cases 
(5.2%) and was presumed based on the combination of imaging 
and paired glucose and insulin results on the remaining 40 cases 
(34.5%). Seven cases did not have histopathology performed 
after surgery; reasons for this included financial constraints of 
owners (four), incomplete clinical records (two) and euthanasia 
after surgery (one). Two cases (1.7%) had a post-mortem exami-
nation histopathology, which confirmed a neuroendocrine car-
cinoma.
Treatment
Thirty-nine cases (33.6%) were treated medically, and 77 
(66.4%) were treated surgically. In the medically treated group, 
seven of 39 had an abnormal neurological examination, 25 of 
39 were classified as WHO stage I, eight of 39 WHO stage II 
and six of 39 WHO stage III. As treatment modalities, 25 of 
39 received glucocorticoids, 18 of 39 special dietary recommen-
dations (consisting of reduced and complex carbohydrate food 
and frequent small meals), six of 39 diazoxide, three of 39 leve-
tiracetam and one of 39 carboplatin. In the surgical group, 16 
of 77 had an abnormal neurological examination, 31 of 77 were 
classified as WHO stage I, 33 of 77 WHO stage II and 13 of 77 
WHO stage III. After the surgical procedure, 36 of 77 received 
glucocorticoids, 19 of 77 special dietary recommendations, 11 of 
77 diazoxide and 2 of 77 toceranib. Furthermore, 16 of 77 dogs 
required insulin (one developed diabetic ketoacidosis) and seven 
of 77 developed signs of acute pancreatitis.
Survival analysis
Follow-up was available for 102 (87.9%) dogs. Of these, nine 
(8.8%) were euthanised immediately (within 24 hours of diag-
nosis) before assignment to any of the two treatment groups and 
therefore they were dropped from survival analysis. Abnormal 
neurological examination (considered as a yes or no answer) did 
not prove to be a significant risk factor of immediate euthanasia 
(OR 3.8; CI 95%: 0.90, 15.4; P=0.110). Of 93 dogs assigned to 
treatment groups, date of death of 61 dogs (65.6%) was known. 
The remaining 32 dogs (34.4%) were still alive at the time of 
data collection and were considered as censored observations.
Characteristics of the two treatment groups included in the 
survival analysis are presented in Table  4 and Data S3. In the 
univariate analysis, 25 characteristics were included. The median 
overall survival differed significantly between types of treat-
ment (HR 0.36; CI 95%: 0.20, 0.64; P=0.001) – it was only 
8  months (IQR from 3 to 16 months) for dogs treated medi-
cally and 20 months (IQR from 9 to 43 months) for dogs that 
had undergone surgery. The only other factor significantly linked 
to overall survival in the univariable analysis was castration with 
the median (IQR) overall survival of 22 (9 to 43) months for 
castrated dogs and 9 (3 to 24) months for entire dogs regard-
less of their sex (HR 0.54; CI 95%: 0.32, 0.91; P=0.020) (Data 
S4). Except for the type of treatment, eight potential confound-
ers were subsequently included in the multivariable analysis in 
order to exclude accidental relationships, these were: age at pre-
sentation, castration, epileptic seizures at presentation, glucose 
concentration at presentation, WHO stage II or III (i.e. presence 
of metastases), using corticosteroids, diazoxide and special diet. 
The surgical treatment was an independent factor significantly 
and consistently reducing the risk of death (HRadjusted 0.34; CI 
95%: 0.19, 0.61; P < 0.001), when controlled for various combi-
nations of the aforementioned potential confounders (Data S5). 
The patients that had undergone surgery were three times less 
likely to die of any reason compared to the patients treated medi-
cally (Table 5). The proportion of patients who survived 1 year 
was two times higher among those than had undergone surgery, 
and the proportion of patients who survived 2 years was sixfold 
higher among those that had undergone surgery compared to 
those medically treated. Only dogs treated with surgery had 
any chance to stay alive for as long as 3 or even 4 years (Table 6, 
Canine insulinoma: presentation and outcome
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Fig 1). The only other variable found to be significantly linked 
to overall survival in the multivariate analysis was the presence of 
metastases (HRadjusted 1.72; CI 95%: 1.02, 2.91; P=0.042) – the 
patient with WHO stage II or III was approximately 1.5- to two-
fold more likely to die regardless of the type of treatment (Table 5 
and Data S5).
Due to concerns over the impact of the high proportion of 
censored cases during the first 6 months in the medical group 
(8/28 dogs; 29%), the analysis of overall survival was performed 
repeatedly replacing records for all dogs, which had been cen-
sored in the medical group with 24-month overall survival but 
without changing the overall survival of dogs in the surgical 
group. Results still suggested that dogs treated surgically had a 
significant longer overall survival (HRadjusted 0.45; CI 95%: 0.27, 
0.75; P=0.002).
DISCUSSION
This study reviewed the clinical findings, neurological manifesta-
tions and survival in a large population of dogs with insulinoma 
over the last decade across referral centres of the United Kingdom 
and Spain.
Weakness (59.5% cases) was the most common presenting 
clinical complaint, followed by generalised epileptic seizures 
(31% cases) and changes in consciousness or behaviour (27.6% 
cases). Hence, based on our results and a review of the litera-
ture, the clinical signs of canine insulinoma seem to be quite 
variable (Trifonidou et al. 1998, Ettinger et al. 2017). The pre-
disposition for older, medium to large breed dogs is consistent 
with previously published values (Dunn et al. 1993, Trifonidou 
et al. 1998). Interestingly, the West Highland White Terrier was 
observed to be the second most common breed in our popula-
tion (12/116 cases, 10.3%), which has also been observed in two 
recent publications with a similar incidence (Cleland et al. 2020, 
Del Busto et al.  2020). The average duration of clinical signs 
before presentation (1.5 months) is in line to recent publications 
reporting 3 to 4 weeks since signs onset (Cleland et al.  2020, 
Del Busto et al.  2020). This is, however, shorter than histori-
cally reported (3 to 5  months) (Dunn et al.  1993, Trifonidou 
et al. 1998). Possible causes for this could be that owners are now 
more alert to subtle changes in their pets and there is increased 
awareness of this condition and availability of imaging tech-
niques, which could have resulted in dogs presenting with more 
vague clinical signs and are diagnosed earlier.
Interestingly, three dogs were suspected to have paroxysmal 
dyskinesia on presentation, which has not been associated with 
canine insulinoma before. Two of these dogs had normal  glucose 
levels at the initial presentation, normal brain MRI and cerebro-
spinal fluid analysis. The presumptive diagnosis was based on the 
owner’s descriptions and videos provided examined by board-
certified neurologists. Despite an encephalogram not being per-
formed in any case to fully exclude focal seizures and the fact that 
we cannot rule out this were two separate conditions occurring at 
the same time, in all 3 cases clinical signs resolved after treatment 
(surgery in two cases and prednisolone in one case). Furthermore, 
an association between paroxysmal dyskinesia and insulinoma 
has been reported in human literature (Shaw et al. 1996,Gupta 
et al.  2011, Deleo et al.  2014, Pozzi et al.  2015). The patho-
physiology is unknown, but it is suspected to be secondary to 
hypoglycaemia causing dysfunction of the corpus striatum. The 
corpus striatum is a brain structure formed by several basal nuclei 
(caudate, accumbens, putamen, pallidum and claustrum) and the 
adjacent white matter, which is involved in motor activity (De 
Lahunta et al. 2015). Dysfunction of the corpus striatum could 
cause lack of inhibition to the thalamus leading to hyperkine-
sias (Shaw et al.  1996). Some of the human patients reported 
did also experience epileptic seizures and neuronal motor axo-
nopathy concurrently (Gupta et al.  2011, Deleo et al.  2014, 
Pozzi et al.  2015). Movement disorders constitute a novel and 
constantly evolving group of conditions that could be misdiag-
nosed as epileptic seizures (Lowrie & Garosi 2017). These cases 
highlight the importance of considering and excluding systemic 
causes in dogs presenting with suspected movement disorders.
A large proportion of dogs presented with clinical signs con-
sidered to be neurological in origin; however, only a 27.6% 
had an abnormal neurological examination. The most common 
and least surprising abnormality was an obtunded mentation in 
nine of 32 cases but is important to underline other prevalent 
alterations, such as reduced withdrawal reflexes, altered menace 
response, changes in behaviour or delayed proprioception. The 
most frequent neurolocalisation was diffuse forebrain. Surpris-
ingly, six dogs presented with focal forebrain signs, all of which 
had a normal brain MRI. The lateralisation of the neurological 
signs could be secondary to postictal changes in cases with epilep-
tic seizures (even if bilateral post-ictal signs are more common) or 
secondary to a vascular event not observed in the MRI. In addi-
tion, four dogs presenting with epileptic seizures were classified 
as multifocal, localising in the forebrain but also in T3-L3 spinal 
cord segments. The suspected myelopathy was not investigated 
in any case as work-up for the epileptic seizures was prioritised. 
Considering the age of the patients, these findings were consid-
ered most likely incidental and secondary to chronic degenerative 
intervertebral disc disease, but other causes of myelopathy were 
not fully excluded. The second most common neurolocalisation 
was diffuse peripheral nervous system. There are few reports of 
subclinical and clinical polyneuropathy in dogs with concurrent 
insulinoma. They all documented similar electrophysiological 
findings to the one dog from our study, which presented with 
non-ambulatory tetraparesis and reduced limb tone (Van Ham 
et al. 1997). The pathophysiology of this polyneuropathy is still 
unknown, but it is believed that the peripheral nervous system 
is quite resistant to hypoglycaemia, and therefore an immune 
Table 5. The Cox proportional hazard model showing the 
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mediated paraneoplastic syndrome is considered to be the most 
likely cause of the clinical signs (Jaspan et al. 1982). Overall, the 
combination of clinical signs and neurological manifestations in 
this cohort further highlights how vague, non-specific and pos-
sibly misleading signs appear to be in dogs presenting with insu-
linoma.
With regards to diagnostic test results, 94% (109/116) cases 
were hypoglycaemic at initial presentation. This emphasises the 
fact that a normal serum glucose concentration at presentation, 
even if uncommon, does not completely exclude insulinoma and 
glucose monitoring should be considered in cases presenting with 
compatible signs. In this study, imaging diagnostic performance 
was similar to previous reports, with CT being more sensitive 
than US (Robben et al. 2005). Nevertheless, there were still cases 
that were missed by either one or both modalities, showing no 
imaging modality is 100% sensitive.
The overall survival of medically treated dogs in our study, 
8 months, was higher than previous reports of 2.4 to 6.5 months 
(Tobin et al. 1999, Polton et al. 2007). This group had a high 
proportion (57%) of WHO stage I cases, which could have 
influenced the overall survival. Nevertheless, this still constitutes 
a valuable reminder of this treatment modality. The surgical 
group achieved significantly longer overall survival (20 months), 
which correlates with previous reports comparing medical and 
surgical cases (Goutal et al. 2012,Cleland et al. 2020, Del Busto 
et al. 2020). Survival analysis suggested that the proportions of 
dogs treated surgically were two- and six- fold more likely to live 
1 and 2 years, respectively, compared to medically treated dogs. 
In addition, the presence of metastases at diagnosis was the only 
other variable that affected overall survival as previously reported 
(Cleland et al. 2020, Del Busto et al. 2020).
The decision on treatment modality can be affected by 
many factors: severity of clinical signs, presence of metasta-
sis, clinicians’ recommendations, surgeons’ expertise, finan-
cial limitations, etc. In this study, and despite its retrospective 
nature, there were no differences found between the measured 
demographics of either group. Interestingly, and opposite to 
what could be expected, the surgical group had a higher pro-
portion of dogs with metastasis than the medical group and 
still achieved a longer overall survival. This could be due to 
some metastasis being detected during exploratory surgery, or 
to owner’s perception of the disease influencing decision on a 
treatment modality. However, further prospective studies con-
trolling all the above variables would be ultimately required to 
confirm if surgery is the gold standard treatment as well as what 
influences treatment decision.
Finally, dogs with an abnormal neurological examination did 
not show a difference of overall survival regardless of the treat-
ment type, nor were they more likely to be euthanised on pre-
sentation. As the neurological examination findings could have a 
subjective interpretation between clinicians, only the presence of 
abnormalities in the neurological examination (yes or no answer) 
was considered for survival analysis. These results were unex-
pected and might suggest that the severity of the neurological 
examination is not correlated with the severity of the disease, but 
to hypoglycaemia that can be successfully managed with treat-
ment. Therefore, it appears that abnormal neurological examina-
tion at presentation is not correlated with prognosis.
This study has some limitations. Firstly, its retrospective nature 
across multiple centres resulted in no standardisation of anamne-
sis, neurological examination records, confirmed histopathologi-
cal diagnosis, treatment or follow-up for the dogs included. This 
could have had an impact on the accuracy of the description of 
the clinical signs, as well as the clinical record completeness. In 
addition, we cannot fully exclude concurrent conditions contrib-
uting to the clinical signs or survival analysis. Although statistical 
significance was achieved in survival analysis, incomplete follow-
up survival data could limit the accuracy of this. Postoperative 
hypoglycaemia has been described as predictor for relapse and 
survival in dogs surgically treated, which was not assessed or 
recorded consistently in all cases (Cleland et al. 2020, Del Busto 
Table 6. Summary of the survival rate expressed as Kaplan–Meier estimates for the surgical and medical group
Time 
(months)
Surgical group (n=65) Medical group (n=28)














1 89.2 (78.7, 94.7) 60 0 5 82.0 (62.0, 92.1) 22 1 5
6 77.7 (65.1, 86.1) 46 6 8 53.8 (31.6, 71.7) 9 7 6
12 70.3 (57.0, 80.2) 40 3 3 33.6 (13.6, 55.2) 6 1 2
24 41.4 (27.9, 54.4) 21 5 14 6.7 (0.5, 26.0) 2 0 4
36 31.7 (19.1, 45.1) 10 5 6 0 1 0 1
48 8.1 (1.6, 21.8) 4 2 4 0 - - -
FIG 1. Kaplan–Meier plot indicating survival for dogs that received 
medical therapy (median 8 months) compared with dogs that had surgery 
(median 20 months)
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et al. 2020). Finally, the dogs included in this study were from a 
referral population, which might not be fully representative of all 
cases of canine insulinoma.
In conclusion, canine insulinoma appears to be diagnosed 
earlier than historically reported and vague, non-specific clinical 
signs are common. Weakness, epileptic seizures and changes in 
mentation or behaviour were the most common clinical findings. 
The most frequent neurological manifestation was an obtunded 
mentation and the most common neurolocalisation was diffuse 
forebrain. Dogs undergoing surgery had a longer overall survival 
compared to medically treated cases, and dogs with metastasis 
had a shorter overall survival regardless of treatment modality. 
Abnormalities in the neurological examination did not correlate 
with prognosis.
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